N-acetyl Epitalon
Aliases: N-acetyl Epithalon · Acetylated AEDG
Last verified: 2026-09-24
The short version
N-acetyl Epitalon is the 'Epitalon 2.0' story: take a molecule without evidence, add a modification with a reasonable pharmaceutical rationale (stability), and get a product that sounds advanced and has nothing. Peptide acetylation is a legitimate strategy (it is done with semaglutide and others), but the legitimacy of the technique is not proof about the concrete product. For comparison: for the 'telomerase' claims of base Epitalon there are at least archaic papers; for the acetylated form not even that exists. Buying this product is buying belief in two steps at once.
Identity & type
- Molecular type
- analog
- Sequence / structure
- N-acetyl-Ala-Glu-Asp-Gly
- Molecular weight
- ~432 Da
- Origin
- A modification of the Khavinson tetrapeptide for greater stability; not part of the original program.
Mechanism of action
An acetylated variant of Epitalon (Ala-Glu-Asp-Gly): the N-acetyl group increases resistance to aminopeptidases and prolongs circulating half-life; its pharmacology leans entirely on base Epitalon — claims about telomerase and pineal function — without a single published study of the acetylated form.
not confirmed in humans
Dosing & routes
Official / clinical context
No official context exists.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Among users already taking 'bioregulators': 1–5 mg SC, 10–20 day cycles, 1–2× yearly; subjective reports are identical to those for plain Epitalon (sleep, 'tone'), which is expected if the effect is placebo.
Unverified self-reports. Not medical advice. Not endorsement.
Protocol — official vs community
Official / label
No approved protocol exists. N-acetyl Epitalon is a vendor derivative of the research peptide Epitalon with no registered drug product and no published study of the acetylated form itself.
Duration: —
The N-acetyl group is claimed to prolong half-life; every pharmacological claim leans on base Epitalon literature.
Community (anecdotal)
Mirrors Epitalon courses: 1–5 mg SC or intranasal daily for 10–20 days, dosed slightly lower than base Epitalon on the assumption of longer availability.
- Cycle:
- 1–2 courses per year, frequently paired with pinealon as for base Epitalon.
- Break:
- Months between courses — built into the model.
The acetylated form has no separate human data; community dosing is an educated scaling of the Epitalon schedule, nothing more.
Human evidence
None for the acetylated form; base Epitalon has no controlled human trials — so nothing and nothing.
Preclinical evidence
Only by analogy to base Epitalon: old, independently unreplicated work by one group.
Known risks
- No significant adverse effects documented in short protocolscharacterized
- Theoretical telomerase-signaling risk as with the base moleculetheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Everything — product identity, pharmacokinetics, effect
Frequently asked questions
References
- No published studies of the acetylated form (as of last verification)